Biomarin Pharmaceutical (BMRN) Other financing activities (2009 - 2025)

Biomarin Pharmaceutical (BMRN) has 17 years of Other financing activities data on file, last reported at $14.5 million in Q4 2025.

• Quarterly Other financing activities rose 83.92% year-over-year to $14.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 70.66% YoY) and the FY2025 annual result came in at $14.5 million, down 70.66% from the prior year.
• Other financing activities advanced to $14.5 million in Q4 2025, from $7.9 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $71.6 million in Q4 2023 to a low of -$52.4 million in Q3 2023.
• A 5-year average of $11.9 million and a median of $14.4 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities jumped 442.98% — and 2023, when it plunged 464.81%.
• Tracing BMRN's Other financing activities over 5 years: stood at -$33.3 million in 2021, then surged by 176.53% to $25.5 million in 2022, then surged by 181.12% to $71.6 million in 2023, then tumbled by 89.02% to $7.9 million in 2024, then soared by 83.92% to $14.5 million in 2025.
• The last three Other financing activities figures came in at $14.5 million (Q4 2025), $7.9 million (Q4 2024), and $4.8 million (Q3 2024), per Business Quant data.